|
Clinical outcomes according to PD-L1 status and age in the prospective international SAUL study of atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract. |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Ipsen; Janssen; Pfizer; Sanofi |
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; Incyte; Ipsen; MSD; Novartis; Pfizer; Roche; Sanofi |
Research Funding - Aragon Pharmaceuticals (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Aveo (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Genzyme (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Myovant Sciences (Inst); Nektar (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst) |
|
|
Honoraria - Astellas Pharma; Janssen-Cilag |
Consulting or Advisory Role - Astellas Pharma; Janssen-Cilag |
Speakers' Bureau - Astellas Pharma; Janssen-Cilag |
Travel, Accommodations, Expenses - Astellas Pharma; Janssen-Cilag |
|
|
Honoraria - Abbvie; Lilly; Merck Serono; Novartis; ObsEva; Pfizer; Radialogica; Regeneron; Roche/Genentech; Sanofi; SynAct Pharma |
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche/Genentech; Sanofi/Regeneron |
Speakers' Bureau - Bristol-Myers Squibb; Janssen; Lilly; Novartis; Pfizer; Regeneron; Roche; Sanofi; UCB |
Research Funding - Bio-Cancer Treatment International (Inst); Biogen (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst) |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi; Sanofi |
Research Funding - Janssen Oncology (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Medivation; Bayer; Clovis Oncology; Ipsen; Janssen; Merck; Roche |
Consulting or Advisory Role - Bayer; Clovis Oncology; Janssen; Merck; Roche |
Speakers' Bureau - Bayer; Ipsen; Janssen; Roche |
Research Funding - Astellas Medivation; AstraZeneca; Bayer; Janssen; Merck; Roche |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Janssen-Cilag; Roche |
Patents, Royalties, Other Intellectual Property - "Deep Learning Motion Algorithm for Lung Cancer Early Detection in Embedded Systems" with ST Microelectronics; "Image processing method, corresponding system and computer program product" with ST Microelectronics |
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; Ipsen; Pierre Fabre |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck; Pfizer; Sanofi |
Research Funding - AstraZeneca (Inst); Roche (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Janssen; Pfizer |
|
|
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Janssen; Roche; Sanofi |
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Janssen; Novartis; Pfizer |
|
|
Honoraria - Bristol-Myers Squibb; Novartis |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Pierre Fabre |
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Novartis; Pfizer |
Research Funding - AstraZeneca; Bristol-Myers Squibb; Novartis; Pfizer; Roche; Sanofi |
Travel, Accommodations, Expenses - Novartis; Pfizer |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Lilly; Pfizer; PharmaMar; Roche |
Speakers' Bureau - Bristol-Myers Squibb; Ipsen; Pfizer; PharmaMar |
Research Funding - AstraZeneca |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; MERCK; Novartis; Pfizer; Roche/Genentech |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Incyte; Ipsen; Merck; Novartis; Novartis; Pfizer; Seagen |
Research Funding - AstraZeneca/MedImmune; Roche/Genentech |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis/Ipsen; Pfizer; Roche/Genentech |
|
|
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Janssen Oncology; MSD Oncology; Roche/Genentech |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Janssen Oncology; MSD Oncology; Novartis; Pharmacyclics; Roche/Genentech; Seagen |
Research Funding - Astellas Pharma (Inst); AstraZeneca Spain (Inst); Janssen Oncology (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - AstraZeneca Spain; Roche/Genentech |
|
|
|
Research Funding - ANZUP Cancer Trials Group Pty (Inst) |
|
|
Honoraria - Alvogen; Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; PharmaSwiss; Roche; Sandoz; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Janssen Biotech; Novartis; Pfizer; Roche; Sanofi |
|
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Pfizer; Roche |
|
|
Honoraria - Bayer Health; Bristol-Myers Squibb; Ipsen; Novartis; Roche; Sanofi/Aventis |
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Roche; Sanofi/Aventis |
Travel, Accommodations, Expenses - Bayer Health; Ipsen; Janssen-Cilag; Novartis; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
Employment - Hayes Schweiz |
|
|
Honoraria - Pfizer; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Incyte; Janssen; Janssen (Inst); MSD Oncology; MSD Oncology (Inst); Roche; Seagen |
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); CureVac (Inst); Exelixis (Inst); Incyte (Inst); Janssen Oncology (Inst); Medivation (Inst); MSD Oncology (Inst); Oncogenex (Inst); Pfizer (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche |